Business & Finance
BioNet and Sartorius' BIA Separations Collaborate on Production Process Development of mRNA Vaccines
3 November 2021 - - French-Thai biotechology company BioNet and Slovenia-based BIA Separations, now part of Sartorius, a biochromatography development and manufacturing company, have developed an optimized mRNA manufacturing process, the companies said.

BIA's expertise in chromatographic columns for mRNA purification combined with BioNet's expertise in the product development of genetic vaccines have, since early 2021, enabled both teams to collaborate on the optimization and upscale of a high-yield mRNA production process.
The new process has been successfully applied to the production of mRNA in the fight against COVID-19.

The mRNA vaccine, produced at BioNet's manufacturing facility, was developed by Chula Vaccine Research Center, Thailand in collaboration with the University of Pennsylvania, US.

Both BIA and BioNet say they are now collaborating on other projects aiming to increase development capabilities and production capacity of nucleic acid vaccines in Europe, Australia, and low-middle income countries.